Huperzine A

American Journal of Health-System Pharmacy

Volumn 57, Issue 6, 2000, Pages 530-534

  Pepping, Joseph ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUPERZINE A; NEOSTIGMINE; PLANT EXTRACT; SCOPOLAMINE;

ALZHEIMER DISEASE; CALCIUM TRANSPORT; CLINICAL TRIAL; DEMENTIA; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; MOSS; PRIORITY JOURNAL; SHORT SURVEY;

EID: 0034654609     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/57.6.530     Document Type: Short Survey

References (18)

1. Cheng DH, Tang XC. Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities. Pharm Biochem Rehav. 1998; 60:377-86.
2. Patocka J. Huperzine A - an interesting anticholinesterase compound from the Chinese herbal medicine. Acta Med. 1998; 41:155-7.
3. Lin JH, Hu GY, Tang XC. Comparison between huperzine A, tacrine, and E2020 on cholinergic transmission at mouse neuromuscular junction in vitro. Acta Pharmacol Sin. 1997; 18:6-10.
4. Laganiere S, Corey J, Tang XC et al. Acute and chronic studies with the anticholinesterase huperzine A: effect on central nervous system cholinergic parameters. Neuropharmacology. 1991; 30:763-8.
5. Wang H, Tang XC. Anticholinesterase effects of huperzine A, E2020, and tacrine in rats. Acta Pharmacol Sin. 1998; 19:27-30.
6. Zhu XC, Giacobini E. Second generation cholinesterase inhibitors: effect of (L)-huperzine-A on cortical biogenic amines. J Neurosci Res. 1995; 41:828-35.
7. Ye JW, Cai JX, Wang LM et al. Improving effect of huperzine A on spatial working memory in aged monkeys and young adult monkeys with experimental cognitive impairment. J Pharmacol Exp Ther. 1999; 288:814-9.
8. Cheng DH, Ren H, Tang XC. Huperzine A, a novel promising acetylcholinesterase inhibitor. Neuroreport. 1996; 8:97-101.
9. Ved HS, Koenig ML, Dave JR et al. Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate. Neuroreport. 1997; 8:963-8.
10. Lallement G, Veyret J, Masqueliez C et al. Efficacy of huperzine in preventing Soman-induced seizures, neuropathological changes and lethality. Fundam Clin Pharmacol. 1997; 11:387-94.
11. Grunwald J, Raveh L, Doctor BP et al. Huperzine A as a pretreatment candidate drug against nerve agent toxicity. Life Sci. 1994; 54:991-7.
12. Qian BC, Wang M, Zhou ZF et al. Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacol Sin. 1995; 16(5):396-8.
13. Francis PT, Palmer AM, Sims NR et al. Neurochemical studies of early onset Alzheimer's disease. Possible influence on treatment. N Engl J Med. 1985; 313:7-11.
14. Xu SS, Gao ZX, Weng Z et al. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacol Sin. 1995; 16:391-5.
15. Knapp MJ, Knopman DS, Solomon PR et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. JAMA. 1994; 271:985-9.
16. Zhang RW, Tang XC, Man YY et al. Drug evaluation of huperzine A in the treatment of senile memory disorders [in Chinese]. Chung Kuo Yao Li Hsueh Pao. 1991; 12(3): 250-2.
17. Mazurek A. An open label trial of huperzine A in the treatment of Alzheimer's disease. Altern Ther. 1999; 5(2):97-8. Abstract.
18. Cheng YS, Lu CZ, Ying ZL et al. 128 cases of myasthenia gravis treated with huperzine A. New Drugs Clin Rem. 1986; 5:260-2.